Piriformis Syndrome Market Research Report – Forecast to 2027

Global Piriformis Syndrome Market Research Report: By Cause (Trauma, Spasms, Others), Diagnostic Test (MRI, Others), Treatment (Medication, Physical Therapy, Others), Distribution Channel (Retail Pharmacies, Others), End-User – Global Forecast Till 2027

ID: MRFR/Pharma/4788-HCR | February 2021 | Region: Global | 100 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario


The global piriformis syndrome market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the global piriformis syndrome market is expected to register a CAGR of ~ 7.0% during the forecast period of 2018–2023.


Piriformis syndrome is a rare neuromuscular condition that is caused when the piriformis muscle compresses the sciatic nerve. The piriformis muscle is a flat, band-like muscle located in the buttock near the upper region of the hip joint. Piriformis syndrome mostly occurs in adults and can affect individuals from any field and activity levels. The common causes of piriformis syndrome are considered to be trauma, spasms, and overuse injury. Additionally, according to the National Center for Biotechnology Information (NCBI), the piriformis syndrome is more prevalent in patients with pain in the lower back.


The global piriformis syndrome market is majorly driven by the increase in the occurrences of piriformis syndrome, increasing screening, rising safety and success of drug treatments, and the growing geriatric population. The market restraints include the complications of surgeries, lack of awareness about the syndrome, and others. Furthermore, challenges in the diagnosis of the syndrome among the patient pool may hamper the growth of the market.


Research Methodology


Market Research Future research is conducted by industry experts who offer insight into industry structure, market segmentation, treatment assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.



  • Primary Research


Extensive primary research was conducted to gain a deeper insight into the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.



  • Secondary Research


Secondary research was mainly used to collect and identify information useful for an extensive, technical, market-oriented, and commercial study of the piriformis syndrome market. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and treatment perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, the international organization of chemical manufacturers, some paid databases and many others.


Company Profiles    



  • Bayer AG

  • Novartis AG

  • AstraZeneca

  • Endo Pharmaceuticals

  • Teva Pharmaceuticals

  • Omron Healthcare

  • Sanofi S.A.

  • DePuy Synthes Companies

  • Miracle Stretch, LLC

  • Flex Pharma, Inc.

  • Nidd valley medical

  • SEIRIN Corporation

  • Others


Segmentation


The global piriformis syndrome market is segmented on the basis of cause, diagnostic test, treatment, distribution channel, and end-user.


On the basis of cause, the market is classified as trauma, spasms, overuse injury, and others.


The piriformis syndrome market on the basis of diagnostic tests is segmented as Magnetic Resonance Imaging (MRI), X-ray, Computed Tomography (CT), neurophysiologic testing, Electromyography (EMG), Beatty Test, FAIR (Flexion, adduction, and Internal Rotation) test, and others.


On the basis of treatment, the market is segmented into medication, physical therapy, acupuncture, prolotherapy, Osteopathic Manipulative Treatment (OMT), surgery, and others. The medication is further segmented into Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), piriformis muscle injection, and others. NSAIDs are further segmented into naproxen, ibuprofen, and others. Further, the piriformis muscle injection is segmented into Botox injection, steroid injections, and others.


The global piriformis syndrome market, by distribution channel, is segmented into E-commerce, retail pharmacies, and others.


On the basis of end-user, the global piriformis syndrome market is segmented as hospitals and clinics, diagnostic centers, and others.


Geographically, the global piriformis syndrome market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The American piriformis syndrome market is further segmented into North America and South America. North America is further classified as the US and Canada.


The European piriformis syndrome market is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.


The piriformis syndrome market in Asia-Pacific is segmented into Japan, China, India, the Republic of Korea, Australia, and the Rest of Asia-Pacific.


The Middle Eastern and African piriformis syndrome market is segmented into the Middle East and Africa.


Regional Market Summary


Global Piriformis Syndrome Market, by Region Market Share, 2017 (%)


Piriformis Syndrome Market


Source: MRFR Analysis


The global piriformis syndrome market consists of four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The North American region is anticipated to dominate the market due to the existing well-established healthcare system, increasing healthcare expenditure, growing awareness about the syndrome, and rising geriatric population. For instance, according to the Centers for Disease Control and Prevention, in 2015, the total health expenditure in the US was reported to be 3.2 USD trillion. Additionally, the high concentration of major hospitals in developed countries of this region coupled with good reimbursement rates is fueling the growth of the market. Moreover, a large number of prominent companies in the US is likely to contribute to the faster development of the piriformis syndrome market in this region.


Europe is expected to hold the second largest market share in the global piriformis syndrome market. It is expected that the government support towards research and development expenditure and increasing secondary lifestyle are likely to drive the market.  Moreover, the market growth in Europe is led by countries such as Germany and France.


The piriformis syndrome market in Asia-Pacific consists of countries, namely, China, Japan, the Republic of Korea, India, Australia, and the rest of Asia-Pacific. The market growth in this region is driven by the rising healthcare expenditure and growing penetration of the healthcare industry in this region.


The Middle East & Africa holds the lowest share of the global piriformis syndrome market. The African region is anticipated to witness a poor market growth owing to poor economic and political conditions and poor healthcare infrastructure.


Global Piriformis Syndrome Market, by Cause



  • Trauma

  • Spasms

  • Overuse injury

  • Others


Global Piriformis Syndrome Market, by Diagnostic Test



  • Magnetic Resonance Imaging (MRI)

  • Computed Tomography (CT)

  • X-rays

  • Neurophysiologic Testing

  • Electromyography (EMG)

  • Beatty Test

  • FAIR (Flexion, adduction, and Internal Rotation) Test

  • Others


Global Piriformis Syndrome Market, by Treatment



  • Medication

  • NSAIDS

  • Naproxen

  • Ibuprofen

  • Others

  • Piriformis Muscle Injection

  • Botox Injection

  • Steroid Injection

  • Others

  • Physical Therapy

  • Acupuncture

  • Prolotherapy

  • Osteopathic Manipulative Treatment (OMT)

  • Surgery

  • Others


Global Piriformis Syndrome Market, by Distribution Channel



  • E-Commerce

  • Retail Pharmacies

  • Others


Global Piriformis Syndrome Market, by End-User



  • Hospitals & Clinics

  • Diagnostic Centers

  • Others


Global Piriformis Syndrome Market, by Region



  • Americas

  • North America

  • US

  • Canada

  • South America

  • Europe

  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe

  • Asia-Pacific

  • Japan

  • China

  • India

  • Australia

  • Republic of Korea

  • Rest of Asia-Pacific

  • The Middle East & Africa

  • Middle East

  • Africa


Intended Audience



  • Pharmaceutical Companies

  • Research and Development (R&D) Companies

  • Diagnostic Laboratories

  • Government Research Institute

  • Academic Institutes and Universities



Frequently Asked Questions (FAQ) :


Major piriformis syndrome market drivers are increasing screening, rising safety and success of drug treatments, the occurrences of piriformis syndrome, and the growing geriatric population.

The piriformis syndrome market study would include surgery, physical therapy, medication, prolotherapy, acupuncture, Osteopathic Manipulative Treatment (OMT), and others.

Piriformis syndrome market study includes diagnostic centers, hospitals and clinics, and others.

The distribution channels are retail pharmacies, E-commerce, and others in piriformis syndrome market study.

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Piriformis Syndrome Market, by Cause

6.1 Introduction

6.2 Trauma

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3 Spasms

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.4 Overuse Injury

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.5 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 7. Global Piriformis Syndrome Market, by Diagnostic Test

7.1 Introduction

7.2 Magnetic Resonance Imaging (MRI)

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3 Computed Tomography (CT)

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.4 X-rays

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.5 Neurophysiologic Testing

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.6 Electromyography (EMG)

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.7 Beatty Test

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.8 FAIR (Flexion, adduction, and Internal Rotation) Test

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.9 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 8. Global Piriformis Syndrome Market, by Treatment

8.1 Introduction

8.2 Medications

8.2.1 NSAIDs

8.2.1.1 Naproxen

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.2.1.2 Ibuprofen

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.2.1.3 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.2.2 Piriformis Muscle Injection

8.2.2.1 Botox Injection

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.2.2.2 Steroid Injection

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.2.2.3 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.3 Physical Therapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.4 Acupuncture

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.5 Prolotherapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.6 Osteopathic Manipulative Treatment (OMT)

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.7 Surgery

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.7 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 9. Global Piriformis Syndrome Market, by Distribution Channel

9.1 Introduction

9.2 E-Commerce

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

9.3 Retail Pharmacies

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

9.4 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 10. Global Piriformis Syndrome Market, by End-User

10.1 Introduction

10.2 Hospitals and Clinics

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

10.3 Diagnostic Centers

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

10.4 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 11. Global Piriformis Syndrome Market, by Region

11.1 Introduction

11.2 Americas

11.2.1 North America

11.2.1.1 US

11.2.1.2 Canada

11.2.2 South America

11.3 Europe

11.3.1 Western Europe

11.3.1.1 Germany

11.3.1.2 France

11.3.1.3 Italy

11.3.1.4 Spain

11.3.1.5 UK

11.3.1.6 Rest of Western Europe

11.3.2 Eastern Europe

11.4 Asia-Pacific

11.4.1 Japan

11.4.2 China

11.4.3 India

11.4.4 Australia

11.4.5 Republic of Korea

11.4.6 Rest of Asia-Pacific

11.5 The Middle East & Africa

11.5.1 The Middle East

11.5.2 Africa

Chapter 12. Company Landscape

12.1 Introduction

12.2 Market Share Analysis

12.3 Key Development & Strategies

Chapter 13. Company Profiles

13.1 Bayer AG

13.1.1 Company Overview

13.1.2 Product Overview

13.1.3 Financials Overview

13.1.4 Key Developments

13.1.5 SWOT Analysis

13.2 Novartis AG

13.2.1 Company Overview

13.2.2 Product Overview

13.2.3 Financial Overview

13.2.4 Key Developments

13.2.5 SWOT Analysis

13.3 AstraZeneca

13.3.1 Company Overview

13.3.2 Product Overview

13.3.3 Financial Overview

13.3.4 Key Development

13.3.5 SWOT Analysis

13.4 Endo Pharmaceuticals

13.4.1 Company Overview

13.4.2 Technology/Business Segment Overview

13.4.3 Financial Overview

13.4.4 Key Development

13.4.5 SWOT Analysis

13.5 Teva Pharmaceuticals

13.5.1 Company Overview

13.5.2 Product Overview

13.5.3 Financial overview

13.5.4 Key Developments

13.5.5 SWOT Analysis

13.6 Omron Healthcare

13.6.1 Company Overview

13.6.2 Product Overview

13.6.3 Financial Overview

13.6.4 Key Developments

13.6.5 SWOT Analysis

13.7 Sanofi S.A.

13.7.1 Overview

13.7.2 Product Overview

13.7.3 Financial Overview

13.7.4 Key Developments

13.7.5 SWOT Analysis

13.8 DePuy Synthes Companies

13.8.1 Overview

13.8.2 Product/ Technology Overview

13.8.3 Financials

13.8.4 Key Developments

13.8.5 SWOT Analysis

13.9 Miracle Stretch, LLC

13.9.1 Overview

13.9.2 Product Overview

13.9.3 Financials

13.9.4 Key Developments

13.9.5 SWOT Analysis

13.10 Flex Pharma, Inc.

13.10.1 Overview

13.10.2 Product Overview

13.10.3 Financials

13.10.4 Key Developments

13.10.5 SWOT Analysis

13.11 Nidd Valley Medical

13.11.1 Overview

13.11.2 Product Overview

13.11.3 Financials

13.11.4 Key Developments

13.11.5 SWOT Analysis

13.12 SEIRIN Corporation

13.12.1 Overview

13.12.2 Product Overview

13.12.3 Financials

13.12.4 Key Developments

13.12.5 SWOT Analysis

13.13 Others

13.13.1 Overview

13.13.2 Product Overview

13.13.3 Financials

13.13.4 Key Developments

13.13.5 SWOT Analysis

Chapter 14 MRFR Conclusion

14.1 Key Findings

14.1.1 From CEO’s View Point

14.1.2 Unmet Needs of the Market

14.2 Key Companies to Watch

14.3 Prediction of the Global Piriformis Syndrome Industry

Chapter 15 Appendix

LIST OF TABLES

Table 1 Global Piriformis Syndrome Market Synopsis, 2020–2027

Table 2 Global Piriformis Syndrome Market Estimates and Forecast, 2020–2027, (USD Million)

Table 3 Global Piriformis Syndrome Market, by Region, 2020–2027, (USD Million)

Table 4 Global Piriformis Syndrome Market, by Cause, 2020–2027, (USD Million)

Table 5 Global Piriformis Syndrome Market, by Diagnostic Test, 2020–2027, (USD Million)

Table 6 Global Piriformis Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 7 Global Piriformis Syndrome Market, by Distribution Channel, 2020–2027, (USD Million)

Table 8 Global Piriformis Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 9 North America Piriformis Syndrome Market, by Cause, 2020–2027, (USD

Million)

Table 10 North America Piriformis Syndrome Market, by Diagnostic Test, 2020–2027, (USD

Million)

Table 11 North America Piriformis Syndrome Market, by Treatment, 2020–2027, (USD

Million)

Table 12 North America Piriformis Syndrome Market, by Distribution Channel, 2020–2027, (USD

Million)

Table 13 North America Piriformis Syndrome Market, by End-User, 2020–2027, (USD

Million)

Table 14 US Piriformis Syndrome Market, by Cause, 2020–2027, (USD Million)

Table 15 US Piriformis Syndrome Market, by Diagnostic Test, 2020–2027, (USD Million)

Table 16 US Piriformis Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 17 US Piriformis Syndrome Market, by Distribution Channel, 2020–2027, (USD Million)

Table 18 US Piriformis Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 19 Canada Piriformis Syndrome Market, by Cause, 2020–2027, (USD Million)

Table 20 Canada Piriformis Syndrome Market, by Diagnostic Test, 2020–2027, (USD Million)

Table 21 Canada Piriformis Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 22 Canada Piriformis Syndrome Market, by Distribution Channel, 2020–2027, (USD Million)

Table 23 Canada Piriformis Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 24 South America Piriformis Syndrome Market, by Cause, 2020–2027, (USD Million)

Table 25 South America Piriformis Syndrome Market, by Diagnostic Test, 2020–2027, (USD

Million)

Table 26 South America Piriformis Syndrome Market, by Treatment, 2020–2027, (USD

Million)

Table 27 South America Piriformis Syndrome Market, by Distribution Channel, 2020–2027,

(USD Million)

Table 28 South America Piriformis Syndrome Market, by End-User, 2020–2027, (USD

Million)

Table 29 Europe Piriformis Syndrome Market, by Cause, 2020–2027, (USD Million)

Table 30 Europe Piriformis Syndrome Market, by Diagnostic Test, 2020–2027, (USD Million)

Table 31 Europe Piriformis Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 32 Europe Piriformis Syndrome Market, by Distribution Channel, 2020–2027, (USD

Million)

Table 33 Europe Piriformis Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 34 Western Europe Piriformis Syndrome Market, by Cause, 2020–2027, (USD

Million)

Table 35 Western Europe Piriformis Syndrome Market, by Diagnostic Test, 2020–2027, (USD

Million)

Table 36 Western Europe Piriformis Syndrome Market, by Treatment, 2020–2027,

(USD Million)

Table 37 Western Europe Piriformis Syndrome Market, by Distribution Channel, 2020–2027,

(USD Million)

Table 38 Western Europe Piriformis Syndrome Market, by End-User, 2020–2027, (USD

Million)

Table 39 Eastern Europe Piriformis Syndrome Market, by Cause, 2020–2027, (USD

Million)

Table 40 Eastern Europe Piriformis Syndrome Market, by Diagnostic Test, 2020–2027, (USD

Million)

Table 41 Eastern Europe Piriformis Syndrome Market, by Treatment, 2020–2027,

(USD Million)

Table 42 Eastern Europe Piriformis Syndrome Market, by Distribution Channel, 2020–2027,

(USD Million)

Table 43 Eastern Europe Piriformis Syndrome Market, by End-User, 2020–2027, (USD

Million)

Table 44 Asia-Pacific Piriformis Syndrome Market, by Cause, 2020–2027, (USD

Million)

Table 45 Asia-Pacific Piriformis Syndrome Market, by Diagnostic Test, 2020–2027, (USD

Million)

Table 46 Asia-Pacific Piriformis Syndrome Market, by Treatment, 2020–2027, (USD

Million)

Table 47 Asia-Pacific Piriformis Syndrome Market, by Distribution Channel, 2020–2027, (USD

Million)

Table 48 Asia-Pacific Piriformis Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 49 Middle East & Africa Piriformis Syndrome Market, by Cause, 2020–2027,

(USD Million)

Table 50 Middle East & Africa Piriformis Syndrome Market, by Diagnostic Test, 2020–2027,

(USD Million)

Table 51 Middle East & Africa Piriformis Syndrome Market, by Treatment, 2020–2027,

(USD Million)

Table 52 Middle East & Africa Piriformis Syndrome Market, by Distribution Channel, 2020–2027,

(USD Million)

Table 53 Middle East & Africa Piriformis Syndrome Market, by End-User, 2020–2027, (USD

Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Piriformis Syndrome Market

Figure 3 Segmentation Market Dynamics for Global Piriformis Syndrome Market

Figure 4 Global Piriformis Syndrome Market Share, by Cause, 2020

Figure 5 Global Piriformis Syndrome Market Share, by Diagnostic Test, 2020

Figure 6 Global Piriformis Syndrome Market Share, by Treatment, 2020

Figure 7 Global Piriformis Syndrome Market Share, by Distribution Channel, 2020

Figure 8 Global Piriformis Syndrome Market Share, by End-User, 2020

Figure 9 Global Piriformis Syndrome Market Share, by Region, 2020

Figure 10 North America Piriformis Syndrome Market Share, by Country, 2020

Figure 11 Europe Piriformis Syndrome Market Share, by Country, 2020

Figure 12 Asia-Pacific Piriformis Syndrome Market Share, by Country, 2020

Figure 13 Middle East & Africa Piriformis Syndrome Market Share, by Country, 2020

Figure 14 Global Piriformis Syndrome Market: Company Share Analysis, 2020 (%)

Figure 15 Bayer AG: Key Financials

Figure 16 Bayer AG: Segmental Revenue

Figure 17 Bayer AG: Geographical Revenue

Figure 18 Novartis AG: Key Financials

Figure 19 Novartis AG: Segmental Revenue

Figure 20 Novartis AG: Geographical Revenue

Figure 21 AstraZeneca:: Key Financials

Figure 22 AstraZeneca: Segmental Revenue

Figure 23 AstraZeneca: Geographical Revenue

Figure 24 Endo Pharmaceuticals: Key Financials

Figure 25 Endo Pharmaceuticals: Segmental Revenue

Figure 26 Endo Pharmaceuticals: Geographical Revenue

Figure 27 Teva Pharmaceuticals: Key Financials

Figure 28 Teva Pharmaceuticals: Segmental Revenue

Figure 29 Teva Pharmaceuticals. Geographical Revenue

Figure 30 Omron Healthcare: Key Financials

Figure 31 Omron Healthcare: Segmental Revenue

Figure 32 Omron Healthcare: Geographical Revenue

Figure 33 Sanofi S.A.: Key Financials

Figure 34 Sanofi S.A.: Segmental Revenue

Figure 35 Sanofi S.A.: Geographical Revenue

Figure 36 DePuy Synthes Companies: Key Financials

Figure 37 DePuy Synthes Companies: Segmental Revenue

Figure 38 DePuy Synthes Companies: Geographical Revenue

Figure 39 Miracle Stretch, LLC: Key Financials

Figure 40 Miracle Stretch, LLC: Segmental Revenue

Figure 41 Miracle Stretch, LLC: Geographical Revenue

Figure 42 Flex Pharma, Inc.: Key Financials

Figure 43 Flex Pharma, Inc.: Segmental Revenue

Figure 44 Flex Pharma, Inc.: Geographical Revenue

Figure 45 Nidd Valley Medical: Key Financials

Figure 46 Nidd Valley Medical Segmental Revenue

Figure 47 Nidd Valley Medical: Geographical Revenue

Figure 48 SEIRIN Corporation: Key Financials

Figure 49 SEIRIN Corporation: Segmental Revenue

Figure 50 SEIRIN Corporation: Geographical Revenue